ConductScience.org, home

Paper39350366

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.

Jessen F and 44 others. J Prev Alzheimers Dis, 2024. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators. Papers, record 39350366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39350366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.
PubMed
Journal
J Prev Alzheimers Dis
PubMed
Year
2024
PubMed
Publication types
Journal Article, Consensus Statement
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
3.59, provisional
iCite
Revised in PubMed
2026-08-10
PubMed

Authors45

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jessen FF
2Kramberger MGM G
3Angioni DD
4Aarsland DD
5Balasa MM
6Bennys KK
7Boada MM
8Boban MM
9Chincarini AA
10Exalto LL
11Felbecker AA
12Fliessbach KK
13Frisoni GBG B
14Garza-Martínez AJA J
15Grimmer TT
16Hanseeuw BB
17Hort JJ
18Ivanoiu AA
19Klöppel SS
20Krajcovicova LL

Source PubMed

See all 45 authorsDownload CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alzheimer DiseaseMajor topic
Humans
Europe
Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
Drug Development

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135379992New insights into the genetic etiology of Alzheimer's disease and related dementias.Nat Genet2022https://conductscience.org/library/papers/35379992PubMed
235676941Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates.Alzheimers Dement (N Y)2022https://conductscience.org/library/papers/35676941PubMed
337202517Blood biomarkers for Alzheimer's disease in clinical practice and trials.Nat Aging2023https://conductscience.org/library/papers/37202517PubMed
433665337General practitioners' attitude toward early and pre-dementia diagnosis of AD in five European countries-A MOPEAD project survey.Alzheimers Dement (Amst)2021https://conductscience.org/library/papers/33665337PubMed
532738937Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.Lancet2020https://conductscience.org/library/papers/32738937PubMed
635542993Aducanumab: Appropriate Use Recommendations Update.J Prev Alzheimers Dis2022https://conductscience.org/library/papers/35542993PubMed
79447441Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.Int Psychogeriatr1997https://conductscience.org/library/papers/9447441PubMed
831205802Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment.Rand Health Q2019https://conductscience.org/library/papers/31205802PubMed
933170262Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.JAMA Netw Open2020https://conductscience.org/library/papers/33170262PubMed
1036376775The Costs of Dementia in Europe: An Updated Review and Meta-analysis.Pharmacoeconomics2023https://conductscience.org/library/papers/36376775PubMed
1132611641Twenty-seven-year time trends in dementia incidence in Europe and the United States: The Alzheimer Cohorts Consortium.Neurology2020https://conductscience.org/library/papers/32611641PubMed
1237280110Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.Brain2023https://conductscience.org/library/papers/37280110PubMed
1337586881Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.Neurology2023https://conductscience.org/library/papers/37586881PubMed
1436130840β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.Neurology2022https://conductscience.org/library/papers/36130840PubMed
1527582220The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.Nature2016https://conductscience.org/library/papers/27582220PubMed
1636641605Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.J Prev Alzheimers Dis2023https://conductscience.org/library/papers/36641605PubMed
1738235531Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK.Br J Psychiatry2024https://conductscience.org/library/papers/38235531PubMed
1831417957Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.Alzheimers Dement (N Y)2019https://conductscience.org/library/papers/31417957PubMed
1934750815"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.J Am Geriatr Soc2022https://conductscience.org/library/papers/34750815PubMed
2037459141Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/37459141PubMed

See all 31 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42802831Locally deployed large language model for real-world lecanemab eligibility pre-screening.Alzheimers Dement (Amst)2026https://conductscience.org/library/papers/42802831PubMed
42711466Expert opinion on Alzheimer's disease diagnostics and management in Central Eastern European countries representing 88 million population.Neurol Sci2026https://conductscience.org/library/papers/42711466PubMed
42426158Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe.Sci Rep2026https://conductscience.org/library/papers/42426158PubMed
42410071The Protective Effects of Small-Molecule Compound 0242 Against LPS-Induced Neuroinflammation and in P301S Tau Transgenic Mice.Neurochem Res2026https://conductscience.org/library/papers/42410071PubMed
41593034Unmasking the hidden catalyst: How infections trigger Alzheimer's disease.J Alzheimers Dis2026https://conductscience.org/library/papers/41593034PubMed
41113830Fair allocation of telemedical counseling services in early detection of Alzheimer's disease: Empirically informed ethical considerations.Alzheimers Dement (Amst)2025https://conductscience.org/library/papers/41113830PubMed
41102550Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.Neurol Sci2025https://conductscience.org/library/papers/41102550PubMed
40761402Pharmacogenetics or predictive genetics? APOE testing blurs the lines.Front Pharmacol2025https://conductscience.org/library/papers/40761402PubMed
40646652Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer's disease.Alzheimers Res Ther2025https://conductscience.org/library/papers/40646652PubMed
40413561Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC.Alzheimers Res Ther2025https://conductscience.org/library/papers/40413561PubMed
40370494Incorporating individually defined brain health priorities in clinical trial outcomes: the electronic Person-Specific Outcome Measure approach in the United States.Alzheimers Dement (N Y)2025https://conductscience.org/library/papers/40370494PubMed
40205115Impact of dementia-landscaped therapy garden on psychological well-being- A pilot study.J Neural Transm (Vienna)2025https://conductscience.org/library/papers/40205115PubMed
39800469Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.J Prev Alzheimers Dis2025https://conductscience.org/library/papers/39800469PubMed
39596969Trends in Global Burden of Alzheimer's Disease and Other Dementias Attributable to High Fasting Plasma Glucose, 1990-2021.Medicina (Kaunas)2024https://conductscience.org/library/papers/39596969PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39350366

GET https://conductscience.org/api/papers/v1/39350366/authors?page=2